Echo Therapeutics Announces Positive Clinical Trial Results of Symphony®; NOVAVAX Launches Phase I Clinical Trial of A/H5N1 Print E-mail
By Staff and Wire Reports   
Wednesday, 02 May 2012 18:57
Below is a look at some of the headlines for companies that made news in the healthcare sector on May 2, 2012.

Echo Therapeutics, Inc. (Nasdaq: ECTE)
announced positive results from its clinical trial of the Symphony tCGM System in elective cardiac surgery patients. This study is the first of two studies Echo is conducting in critically ill patients, with results from the second study expected later this quarter.

Data from this study demonstrate that Symphony successfully and continuously monitored glucose levels in the cardiothoracic surgical intensive care unit at Tufts Medical Center in Boston, Massachusetts. Data analysis demonstrated that Symphony read glucose levels accurately, with a mean absolute relative difference (MARD), or error rate of 12.3%.


=====


Novavax, Inc. (Nasdaq: NVAX)
announced it has begun enrollment in a Phase I clinical trial of its monovalent virus-like particle (VLP) vaccine candidate to prevent a potential pandemic disease due to A/H5N1 avian influenza viruses.

This randomized, observer-blind, dose-ranging, placebo-controlled trial is being conducted under the company's contract with the U.S. Department of Health and Human Services' Biomedical Advanced Research and Development Authority (HHS BARDA). The goal of the trial is to evaluate the safety of the VLP A/H5N1 avian influenza vaccine candidate Novavax is developing under the HHS BARDA contract and determine the vaccine's immunogenicity with and without the use of an undisclosed adjuvant .

The Phase I trial will enroll healthy adult subjects, each of whom will be randomized into one of six treatment groups including varying doses of A/H5N1 VLP vaccine, with or without Adjuvant 1, or placebo. The trial is being conducted in a stepwise manner, enrolling increasing number of subjects, until a target of approximately 333 subjects is reached. All subjects will be evaluated for safety and immunogenicity. Trial participants will receive two identical intramuscular injections at a 21-day interval (Day 0 and Day 21) with study follow-up approximately 13 months from the first dose.



Also Wednesday:



Advanced Cell Technology, Inc. (OTCBB: ACTC)
, a leader in the field of regenerative medicine, announced today that Massachusetts Eye and Ear (“Mass. Eye and Ear”) has received institutional review board (IRB) approval to be a site for the company’s Phase I/II clinical trial for dry age-related macular degeneration (dry AMD), using human embryonic stem cell (hESC)-derived retinal pigment epithelial (RPE) cells.

Allergan, Inc. (NYSE:AGN)
today announced operating results for the quarter ended March 31, 2012. Allergan also announced that its Board of Directors has declared a first quarter dividend of $0.05 per share, payable on June 14, 2012 to stockholders of record on May 24, 2012.

AVEO Pharmaceuticals Inc. (NASDAQ: AVEO)
announced today preliminary data from the exploratory, randomized Phase 2 study comparing the combination of ficlatuzumab and gefitinib, an EGFR tyrosine kinase inhibitor (TKI), to gefitinib monotherapy in previously untreated Asian subjects with non-small cell lung cancer (NSCLC), a population with a high prevalence of EGFR sensitizing mutations (SM+).

Baxter International Inc. (NYSE: BAX)
announced today that it will present at the Bank of America Merrill Lynch 2012 Healthcare Conference on Wednesday, May 16, 2012, at 11:20 a.m. PT.

Bioanalytical Systems, Inc. (NASDAQ:BASI)
will release financial results for the fiscal 2012 second quarter ended March 31, 2012 at approximately 7:30 a.m. EDT on Friday, May 11, 2012.

Biogen Idec Inc. (NASDAQ: BIIB)
announced today that its presentation at the Deutsche Bank 37th Annual Healthcare Conference will be webcast live on Tuesday, May 8, 2012 at 10:00 a.m. ET.

Charles River Laboratories International, Inc. (NYSE: CRL)
today reported its results for the first quarter of 2012. For the quarter, net sales from continuing operations were $286.0 million, effectively unchanged from $285.8 million in the first quarter of 2011.

Exelixis, Inc. (NASDAQ: EXEL)
announced today that Frank Karbe, the company’s executive vice president and chief financial officer, will present at the upcoming Deutsche Bank Securities 37th Annual Health Care Conference at 4:50 p.m. EDT / 1:50 p.m. PDT on Tuesday, May 8, 2012, in Boston.

Fibrocell Science, Inc. (OTCBB: FCSC)
, an autologous cellular therapeutic company focused on the development of innovative products for aesthetic, medical and scientific applications, announced today that David Pernock, the Company’s Chairman and CEO, will host an investor conference call to discuss Fibrocell’s business update for the first quarter ended March 31, 2012 on Tuesday, May 15, 2012 at 4:30 PM Eastern Time.

Illumina, Inc. (NASDAQ:ILMN)
today announced that it will webcast the Company's presentations at two upcoming investment conferences.

Interleukin Genetics, Inc. (OTCQB: ILIU)
announced today that it will host a conference call and Webcast on Thursday, May 10, 2012 at 4:30 p.m. ET to discuss the Company’s first quarter results.

Lannett Company, Inc. (NYSE Amex: LCI)
, a manufacturer of generic pharmaceuticals, today announced that the company will release its fiscal 2012 third-quarter financial results on Tuesday, May 8, 2012 after the market closes.

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND)
today reported financial results for the first quarter ended March 31, 2012, and provided an operating forecast and program updates.

MannKind Corporation (Nasdaq: MNKD)
will release its 2012 first quarter financial results on Wednesday, May 9, 2012 and its management will host a conference call to discuss the first quarter financial results and other Company developments at 5:00 PM (Eastern Time) on May 9, 2012.

Navidea Biopharmaceuticals, Inc. (NYSE Amex: NAVB)
, a specialty pharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced business highlights and consolidated results for the first quarter ended March 31, 2012.

Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX)
today announced that financial results for the company's first quarter ended March 31, 2012, will be released before the market opens on Wednesday, May 9, 2012.

PharMerica Corporation (NYSE: PMC), a national provider of institutional pharmacy and hospital pharmacy management services, today reported its financial results for the first quarter of 2012.

Solazyme, Inc. (NASDAQ: SZYM)
, a renewable oil and bioproducts company, and The Dow Chemical Company (NYSE: DOW), announced today that they have entered into a contingent offtake agreement in which Dow has agreed to purchase from Solazyme all of its requirements of non-vegetable microbe-based oils for use in dielectric fluid applications through 2015, contingent upon Solazyme’s ability to supply such oils within agreed specifications and certain terms and conditions of the sale.

Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP)
today announced that it will host a webcast and teleconference with senior management to discuss its financial results and operating highlights for the first quarter ended March 31, 2012, on Wednesday, May 9, 2012, at 5:00 pm Eastern.

VentriPoint Diagnostics (TSX VENTURE:VPT) (OTCQX:VPTDF)
today announced the commencement of the pivotal clinical trial to demonstrate that the VentriPoint VMS™ heart analysis system is equivalent to cardiac MRI in patients with pulmonary arterial hypertension (PAH). The trial will be lead by Dr. Robyn Barst.

With new state regulations allowing pharmacists to administer a broad range of immunizations, Walgreens (NYSE: WAG) (NASDAQ: WAG) has significantly expanded vaccine availability at all of its 165 locations across Massachusetts, and is now offering immunizations daily for 12 vaccines currently recommended by the Centers for Disease Control and Prevention (CDC).

Zalicus Inc. (NASDAQ: ZLCS), a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases, today announced that it is advancing Z160, its novel, first in class, oral, N-type calcium channel blocker into multiple Phase 2a clinical trials for chronic pain indications.



"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter